SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shukra Pharmaceuticals informs about closure of trading window

20 Mar 2026 Evaluate
Shukra Pharmaceuticals has informed that the Company is closing its Trading window for dealing in the securities of the Company by the Promoters, members of the Promoter Group, Directors, KMPs, Insiders, Designated and Connected persons and their immediate relatives from Wednesday, April 1, 2026 till 48 hours after the declaration of its Financial Results for the Quarter and Year ended March 31, 2026 pursuant to the provisions of the Clause 4(2) of Schedule B read with Regulation 9 of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (as amended from time to time) and SEBI Circular No. SEBV/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated August 5, 2022 and SEBI/HO/ISD/ISD-PoD-2/P/CIR/2023/124 dated July 19, 2023 read with Company’s ‘Code of Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading in Securities by Designated Persons’ (Insider Trading Code). Accordingly, all the Designated persons (including dependants and immediate relatives as per code) and connected persons are advised not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of trading window. The date of the Board Meeting in connection with publishing its Financial Results for the quarter and year ended March 31, 2026 will be announced in due course.

The above information is a part of company’s filings submitted to BSE.

Shukra Pharma Share Price

33.84 -1.00 (-2.87%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1654.70
Dr. Reddys Lab 1232.00
Cipla 1229.60
Zydus Lifesciences 915.45
Lupin 2332.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×